Banque Cantonale Vaudoise Takes Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Banque Cantonale Vaudoise purchased a new position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 5,560 shares of the biopharmaceutical company’s stock, valued at approximately $1,529,000.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Allspring Global Investments Holdings LLC boosted its stake in Alnylam Pharmaceuticals by 572.0% in the first quarter. Allspring Global Investments Holdings LLC now owns 168 shares of the biopharmaceutical company’s stock valued at $25,000 after acquiring an additional 143 shares during the last quarter. Ashton Thomas Private Wealth LLC bought a new stake in Alnylam Pharmaceuticals during the 2nd quarter worth approximately $26,000. Huntington National Bank increased its holdings in Alnylam Pharmaceuticals by 91.8% during the 3rd quarter. Huntington National Bank now owns 94 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 45 shares during the period. Hollencrest Capital Management bought a new stake in Alnylam Pharmaceuticals during the 3rd quarter worth approximately $29,000. Finally, Altitude Crest Partners Inc. bought a new stake in Alnylam Pharmaceuticals during the 1st quarter worth approximately $30,000. 92.97% of the stock is currently owned by hedge funds and other institutional investors.

Alnylam Pharmaceuticals Trading Up 6.2 %

Shares of ALNY opened at $248.79 on Thursday. The stock has a market capitalization of $32.09 billion, a P/E ratio of -94.96 and a beta of 0.39. The company has a quick ratio of 2.69, a current ratio of 2.75 and a debt-to-equity ratio of 31.64. The firm has a fifty day simple moving average of $273.83 and a two-hundred day simple moving average of $236.76. Alnylam Pharmaceuticals, Inc. has a twelve month low of $141.98 and a twelve month high of $304.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings data on Thursday, October 31st. The biopharmaceutical company reported ($0.87) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.36). The business had revenue of $500.90 million for the quarter, compared to analyst estimates of $532.91 million. During the same period in the previous year, the business earned $1.15 EPS. The company’s quarterly revenue was down 33.3% on a year-over-year basis. On average, research analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -2.22 EPS for the current year.

Analyst Ratings Changes

A number of research firms recently weighed in on ALNY. Wolfe Research lowered shares of Alnylam Pharmaceuticals from a “peer perform” rating to an “underperform” rating in a report on Tuesday, November 12th. Needham & Company LLC reissued a “buy” rating and issued a $320.00 price target on shares of Alnylam Pharmaceuticals in a research note on Friday, November 1st. William Blair reissued an “outperform” rating on shares of Alnylam Pharmaceuticals in a research note on Tuesday. HC Wainwright reissued a “buy” rating and issued a $400.00 price target on shares of Alnylam Pharmaceuticals in a research note on Monday. Finally, The Goldman Sachs Group raised shares of Alnylam Pharmaceuticals from a “neutral” rating to a “buy” rating and boosted their price target for the stock from $198.00 to $370.00 in a research note on Friday, August 16th. One research analyst has rated the stock with a sell rating, five have issued a hold rating and nineteen have issued a buy rating to the company. Based on data from MarketBeat.com, Alnylam Pharmaceuticals has a consensus rating of “Moderate Buy” and an average price target of $298.09.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.